BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hagmarker L, Svensson J, Rydén T, van Essen M, Sundlöv A, Gleisner KS, Gjertsson P, Bernhardt P. Bone Marrow Absorbed Doses and Correlations with Hematologic Response During 177Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases. J Nucl Med 2019;60:1406-13. [PMID: 30902877 DOI: 10.2967/jnumed.118.225235] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Monserrat Fuertes T, González García FM, Peinado Montes MÁ, Domínguez Grande ML, Martín Fernández N, Gómez de Iturriaga Piña A, Mínguez Gabiña P. Description of the methodology for dosimetric quantification in treatments with 177Lu-DOTATATE. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2021;40:167-78. [PMID: 33811003 DOI: 10.1016/j.remn.2021.02.006] [Reference Citation Analysis]
2 Minczeles NS, de Herder WW, Konijnenberg MW, Feelders RA, Brabander T, Hofland J. Dose-Limiting Bone Marrow Toxicities After Peptide Receptor Radionuclide Therapy Are More Prevalent in Women Than in Men. Clin Nucl Med 2022;Publish Ahead of Print. [DOI: 10.1097/rlu.0000000000004203] [Reference Citation Analysis]
3 Mohan V, Bruin NM, van de Kamer JB, Sonke JJ, Vogel WV. The increasing potential of nuclear medicine imaging for the evaluation and reduction of normal tissue toxicity from radiation treatments. Eur J Nucl Med Mol Imaging 2021. [PMID: 33687522 DOI: 10.1007/s00259-021-05284-5] [Reference Citation Analysis]
4 Garcia-Torralba E, Spada F, Lim KHJ, Jacobs T, Barriuso J, Mansoor W, McNamara MG, Hubner RA, Manoharan P, Fazio N, Valle JW, Lamarca A. Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. Cancer Treat Rev 2021;94:102168. [PMID: 33730627 DOI: 10.1016/j.ctrv.2021.102168] [Reference Citation Analysis]
5 Ipek Işıkcı N, Abuqbeitah M, Demir M. The Interference of Gamma Rays With Bone Mineral Density Measurements in 177Lu-PSMA and DOTATATE Therapy. J Clin Densitom 2021:S1094-6950(21)00073-1. [PMID: 34654625 DOI: 10.1016/j.jocd.2021.08.003] [Reference Citation Analysis]
6 Sundlöv A, Gleisner KS, Tennvall J, Ljungberg M, Warfvinge CF, Holgersson K, Hallqvist A, Bernhardt P, Svensson J. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients. Eur J Nucl Med Mol Imaging 2022. [PMID: 35451612 DOI: 10.1007/s00259-022-05786-w] [Reference Citation Analysis]
7 Walrand S, Jamar F. Renal and Red Marrow Dosimetry in Peptide Receptor Radionuclide Therapy: 20 Years of History and Ahead. Int J Mol Sci 2021;22:8326. [PMID: 34361092 DOI: 10.3390/ijms22158326] [Reference Citation Analysis]
8 Sjögreen Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, Konijnenberg M, Cremonesi M, Verburg FA, Bernhardt P, Eberlein U, Gear J. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. [DOI: 10.1007/s00259-022-05727-7] [Reference Citation Analysis]
9 Chatachot K, Shiratori S, Chaiwatanarat T, Khamwan K. Patient dosimetry of 177Lu-PSMA I&T in metastatic prostate cancer treatment: the experience in Thailand. Ann Nucl Med 2021. [PMID: 34309816 DOI: 10.1007/s12149-021-01659-8] [Reference Citation Analysis]
10 Vergnaud L, Giraudet AL, Moreau A, Salvadori J, Imperiale A, Baudier T, Badel JN, Sarrut D. Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle for [Formula: see text]Lu-DOTATATE therapy. EJNMMI Phys 2022;9:37. [PMID: 35575946 DOI: 10.1186/s40658-022-00462-2] [Reference Citation Analysis]
11 Hallqvist A, Svensson J, Hagmarker L, Marin I, Rydén T, Beauregard JM, Bernhardt P. Optimizing the Schedule of PARP Inhibitors in Combination with 177Lu-DOTATATE: A Dosimetry Rationale. Biomedicines 2021;9:1570. [PMID: 34829796 DOI: 10.3390/biomedicines9111570] [Reference Citation Analysis]
12 Kennedy JA, Lugassi R, Gill R, Keidar Z. Digital Solid-State SPECT/CT Quantitation of Absolute 177Lu Radiotracer Concentration: In Vivo and In Vitro Validation. J Nucl Med 2020;61:1381-7. [PMID: 32111686 DOI: 10.2967/jnumed.119.239277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 O'neill E, Cornelissen B. Know thy tumour: Biomarkers to improve treatment of molecular radionuclide therapy. Nuclear Medicine and Biology 2022. [DOI: 10.1016/j.nucmedbio.2022.02.004] [Reference Citation Analysis]
14 Haug AR. PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme? EJNMMI Res 2020;10:35. [PMID: 32296955 DOI: 10.1186/s13550-020-00623-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Marin I, Rydèn T, Van Essen M, Svensson J, Gracheva N, Köster U, Zeevaart JR, van der Meulen NP, Müller C, Bernhardt P. Establishment of a clinical SPECT/CT protocol for imaging of 161Tb. EJNMMI Phys 2020;7:45. [PMID: 32613587 DOI: 10.1186/s40658-020-00314-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
16 Lubberink M, Wilking H, Öst A, Ilan E, Sandström M, Andersson C, Fröss-Baron K, Velikyan I, Sundin A. In Vivo Instability of 177Lu-DOTATATE During Peptide Receptor Radionuclide Therapy. J Nucl Med 2020;61:1337-40. [PMID: 32005767 DOI: 10.2967/jnumed.119.237818] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Rydén T, Van Essen M, Marin I, Svensson J, Bernhardt P. Deep-Learning Generation of Synthetic Intermediate Projections Improves 177Lu SPECT Images Reconstructed with Sparsely Acquired Projections. J Nucl Med 2021;62:528-35. [PMID: 32859710 DOI: 10.2967/jnumed.120.245548] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
18 Thuillier P, Maajem M, Schick U, Blanc-Beguin F, Hennebicq S, Metges JP, Salaun PY, Kerlan V, Bourhis D, Abgral R. Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors: A Feasibility Study. Clin Nucl Med 2021;46:111-8. [PMID: 33234927 DOI: 10.1097/RLU.0000000000003412] [Reference Citation Analysis]